SubHero Banner
Text

July 2019

Core topics in this month’s edition include:

  • Hadlima (adalimumab-bwwd) – new biosimilar approval
  • Kanjinti (trastuzumab-anns) – new biosimilar approval and launch
  • Mvasi (bevacizumab-awwb) – new biosimilar approval and launch
  • Ruxience (rituximab-pvvr) – new biosimilar approval
  • Lyrica (pregabalin) – first time generic

Download PDF